NFKB1 and B-cell chronic lymphocytic leukemia: We propose that targeting non-canonical NF-κB signalling is an attractive therapeutic option in CLL, particularly since its activation following CD40L-mediated signalling demonstrates its important role during the onset of CLL cell proliferation.